Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SUPN with free AI briefings, catalyst countdowns, and dilution alerts.

SUPN · Supernus, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$305M Cash on Hand
CF+ Cash Runway
Follow SUPN by email Get an email when SUPN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SUPN, unsubscribe in one click. Privacy

📣 What SUPN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Brexanolone
FDA approved Mar 2019 · Zulresso (discontinued)
Postpartum Depression Phase 4 · NCT05059600 Completed
SPN-812 Healthy Lactating Women Phase 4 · NCT06259331 Completed
SPN-538 Migraine Disorders Phase 4 · NCT04050293 Terminated
SAGE-718 Huntington's Disease Phase 3 · NCT05655520 Terminated
Molindone Attention Deficit Hyperactivity Disorder (ADHD) Phase 3 · NCT02691182 Terminated
SAGE-547 90 μg/kg/h Postpartum Depression Phase 3 · NCT02942004 Completed
SAGE-547 60 μg/kg/h Postpartum Depression Phase 3 · NCT02942004 Completed
SAGE-547 Super-Refractory Status Epilepticus Phase 3 · NCT02477618 Completed
Apomorphine Idiopathic Parkinson's Disease Phase 3 · NCT02339064 Active not recruiting
NV-5138 Treatment Resistant Depression Phase 2 · NCT05066672 Completed
IR Viloxazine Attention-Deficit/Hyperactivity Disorder (ADHD) Phase 1/2 · NCT01107496 Completed
SPN-817 Epilepsy Phase 2 · NCT05518578 Recruiting
SPN-821 2400 mg Major Depressive Disorder (MDD) Phase 2 · NCT07226661 Recruiting
SAGE-904 Healthy Volunteer Phase 1 · NCT05049343 Completed
Ketamine Healthy Volunteer Phase 1 · NCT05049343 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SUPN holds $305M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SUPN files for a raise →

👥 Who Owns SUPN

Insiders 4.5% Other 5%+ holders 5.4% Institutions (470 holders) 60% Public and other holders 30.1%
HolderTypeShares% of sharesAs of
BlackRock, Inc. Institution (13G, 5%+) 17,806,183 15.09% 2025-12-31
Millennium Management LLC 5%+ holder (13G) 6,343,651 5.37% 2026-09-23
Jack A. Khattar
Chief Executive Officer, Director · +4.34M options
Insider 3,413,555 2.89% 2026-11-02
Vanguard Portfolio Management Institution (13G, 5%+) 3,263,309 2.76% 2026-03-31
Vanguard Capital Management Institution (13G, 5%+) 2,900,884 2.46% 2026-03-31
Joseph Ciaffoni
Chief Executive Officer, Director
Insider 790,330 0.67% 2026-06-22
Ryan Preblick
Chief Financial Officer
Insider 284,751 0.24% 2026-06-08
Christian Heidbreder
Chief Scientific Officer
Insider 209,337 0.18% 2026-07-10
Charles W Iii Newhall
Director
Insider 124,119 0.11% 2026-02-24
Jeffrey W Burris
Chief Legal Officer
Insider 71,518 0.06% 2026-03-03
Frederick M. Hudson
Director
Insider 60,413 0.05% 2026-03-12
Georges Gemayel
Director · +123,818 options
Insider 42,009 0.04% 2026-11-02

Share count 118,035,272 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full SUPN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SUPN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.